Hydroxyurea has been used to treat sickle cell disease (SCD) since the 1980s
This fact sheet will provide the facts about hydroxyurea, potential benefits and risks, and
hydroxyurea therapy (Moderate recommendation, very low quality evidence)
Approval of L-glutamine was based on data from a randomized, placebo-controlled trial in which, over the course of 48 weeks, patients receiving L-glutamine had
demonstrat-ed the efficacy of hydroxyurea in reducing mor-bidity in adults with sickle cell anemia
It raises the level of HbF and the haemoglobin
__________________________________ ______________ PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL (BABY HUG) FOLLOW-UP
The efficacy of hydroxyurea in the treatment of sickle cell disease is generally attributed to its ability to increase fetal hemoglobin (α 2 γ 2)
The Evidence-Based Management of Sickle Cell Disease, Expert Panel Report 2014, is based on the best available but limited evidence
It is currently the staple drug for the management of sickle cell anemia and chronic myeloproliferative disorders
Simple therapy with hydroxyurea (HU) is still not available to the millions in Africa today
Data from the 3647 children and adults with SCD followed prospectively from 1978 to 1988 in the Cooperative Study for Sickle Cell
Abstract
This medicine can decrease pain episodes, frequency of acute chest syndrome, and the need for blood transfusions
Hydroxyurea is an oral medicine that can help reduce sickle cell disease complications
We review the evidence of efficacy and safety in children with reference to pivotal adult studies
Hydroxyurea can help prevent a range of sickle cell disease complications, including vaso-occlusive episodes
Sickle cell anemia (SCA) is one of the most common inherited diseases in the world
Blood 94: 1550–1554 [Google Scholar] Kleinman SH, Hurvitz CG, Goldfinger D 1984
If you have any form of sickle cell disease, hydroxyurea could help you